Quetiapine, an atypical antipsychotic

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1183-1194

  Goren, Jessica L ^a   Levin, Gary M ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Capital District Psychiatric Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL DEPRESSANT AGENT; CIMETIDINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DOPAMINE 2 RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENYTOIN; QUETIAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

ARTICLE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; INSOMNIA; NEUROTRANSMISSION; PATHOPHYSIOLOGY; SCHIZOPHRENIA; SOMNOLENCE; THYROID FUNCTION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DIBENZOTHIAZEPINES; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0031784748     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. American Psychiatric Association. Schizophrenia and other psychotic disorders. In: American Psychiatric Association diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Press, 1994:273-90.
2. Leiberman JA. Atypical antipsychotics as first line treatment of schizophrenia. J Clin Psychiatry 1996;57(suppl 11):68-71.
3. Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand 1994;90(suppl 384):95-101.
4. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenia: a double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
5. Meltzer HY. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1277-86.
6. Fulton B, Goa KL. ICI-204,636. An initial appraisal of its pharmacologic properties and clinical potential in the treatment of schizophrenia. CNS Drugs 1995;4(1):68-78.
7. Schott A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:54-73.
8. Casey DE. Seroquel (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996;5(8):939-57.
9. Goldstein JM, Arvanitis LA. ICI-204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev 1995;1(1):50-73.
10. Richelson E. Preclinical pharmacology of neuroleptics: focus on a new generation compounds. J Clin Psychiatry 1996; 57(suppl 11):4-11.
11. Meltzer HY. Preclinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 1996;168(suppl 29):23-31.
12. Zeneca Pharmaceuticals. Seroquel (quetiapine fumarate) package insert. Wilmington, DE;October 1997.
13. Ereshefsky L. Pharmacokinetics and drug interactions: update for new atypical antipsychotics. J Clin Psychiatry 1996;57(suppl 11):12-25.
14. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
15. Grimm SW, Stams KR, Bui K. In vitro prediction of potential metabolic drug interactions for seroquel [abstr]. Schizophr Res 1997;24:198.
16. Thyrum PT, Jaskiw G, Fuller G, Wong YWJ, Ewing BJ, Yah C. Multiple-dose pharmacokinetics of ICI 204,636 in elderly patients with selected psychotic disorders [abstr]. Psychopharmacol Bull 1996;32:524.
17. Wong YWJ, Ewing BJ, Thyrum PT, Yeh C. Multiple-dose pharmacokinetics of Seroquel (quetiapine) in schizophrenic men and women [abstr]. Schizophr Res 1997;24:200.
18. Mcconville B, Aravanitis L, Wong J, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate in adolescents with selected psychotic disorders. Poster presentation, 38th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June 10-13, 1998.
19. Faber LF, Arvanitis LA, Pultz J, et al. ICI-204,636 a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17(3)366-78.
20. Borison RL, Arvanitis LA, Miller BG, et al. ICI-204,636, an atypical antipsychotic: efficacy and safety in a multicenter placebo controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-69.
21. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double blind comparison with placebo. Arch Gen Psychiatry 1997;54: 549-57.
22. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
23. Casey DE. Side effects of new antipsychotic agents. J Clin Psychiatry 1996;57(suppl 11):40-5.
24. Janssen Pharmaceutica. Risperdal (risperidone) package insert. Titusville, NJ;December 1993.
25. Eli Lilly Industries. Zyprexa (olanzapine) package insert. Carolina, Puerto Rico; September 1996.
26. Umbricht D, Kane JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996;22(3):475-83.
27. Allison DM, Mentore JL, Heo M, Weiden PJ, Cappelleri J, Chandler LP. Weight gain associated with conventional and newer antipsychotics: a meta-analysis. Poster presentation, 38th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June 10-13, 1998.
28. Hamner MB, Arvanitis LA, Miller BG, Link CGG, Hong WW. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996;31(1):107-10.
29. Goldstein JM. Low incidence of reproductive/hormonal side effects with Seroquel (quetiapine fumarate) is supported by its lack of elevation of plasma prolactin concentrations. Poster presentation, 38th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June 10-13, 1998.
30. Wong YWJ, Ewing BJ, Thyrum PT, Yeh C. The effects of phenytoin and cimetidine on the phamacokinetics of seroquel [abstr]. Schizophr Res 1997;24:200.
31. Wong YWJ, Ewing BJ, Thyrum PT, Yeh C, Potkin SG. Effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics of quetiapine [abstr]. Presented at the meeting of the New Clinical Drug Evaluation Unit, Boca Raton FL, May 27-30, 1997.
32. Weiden PJ, Ollson M. Cost of relapse in schizophrenia. Schizophr Bull 995;21(3):419-29.
33. Meise U, Flrischhacker WW. Perspective on treatment needs in schizophrenia. Br J Psychiatry 1996;168(suppl 29):9-16.
34. Hargreaves W, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996;57(suppl 9): 66-76.
35. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63.
36. McEvoy JP, Weiden PJ, Smith TE, Carpenter D, Kahn DA, Frances A. The expert consensus guidelines for the treatment of schizophrenia. J Clin Psychiatry 1996;57(suppl 12B):1-58.
37. Kalali AH, Hellewell JSE, Goldstein JM, Langham S. A multinational survey of patient satisfaction with long term quetiapine fumarate treatment. Poster presentation, 38th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June 10-13, 1998.